1 / 46

Mergers, Acquisitions & Alliances in Emerging Markets

Mergers, Acquisitions & Alliances in Emerging Markets. Dr. Brian W Tempest www.briantempest.com Generics & Biosimilars, CpHI Conference Istanbul, Turkey 19 September 2012.

myrrh
Download Presentation

Mergers, Acquisitions & Alliances in Emerging Markets

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest www.briantempest.com Generics & Biosimilars, CpHI Conference Istanbul, Turkey 19 September 2012

  2. Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world. He is now Independent Chairman of Religare Capital Markets, a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com. Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd

  3. Debt Impacting Global Healthcare

  4. But Healthcare will expand faster in Asia

  5. Pressures on Big Pharma

  6. Pharma Business Modelsource: Pharmatimes World News April 2012

  7. Is the Big Pharma Business Model Sustainable?

  8. One of the largest R&D failures • “Nobody endured these lessons harder than Pfizer. The company built the world’s largest pharmaceutical research centre in Connecticut, USA , a 160 acre site with more than 5,000 employees at its peak and 2.7m sq ft of research space. But the only major drug to come out of the sprawling facility in the past 20 years was the smoking cessation treatment Chantix” Source; Pharmatimes February 2012

  9. But Pharma R&D still needs Fundingsource: FT

  10. So R&D Spend to 2018 is still growingsource: Evaluate pharma 2012

  11. Regulatory Challengessource: Pharmatimes World News Feb 2012

  12. Big Pharma Corporate Fines Source: Daily Mail 3 July 2012

  13. Big Pharma Corporate Finessource: FT August 7 2012

  14. Merck – No 1 Layoffs in 2011 source FiercePharma

  15. Will Big Pharma Change?

  16. Big Pharma Changing Strategies • Share repurchase - Pfizer, Sanofi Aventis • Shedding businesses – Pfizer $1.9b nutrition, $3.6b animal health, £2.4b Capsugel • Eye Care - Novartis & Alcon • Consumer Healthcare – Sanofi Aventis, GSK • Generics – Pfizer, Sanofi Aventis, AZ • Pharmemerging – GSK, Abbott, Daichi Sankyo • OTC – P&G with Teva entering India

  17. Sanofi, GSK, Merck & Novartis cut Pricessource: FT

  18. Following the Asian Growthsource: Bangkok Post 26 July 2012

  19. >60% of GSK is a “non white pill” source: GSK Investor Presentation q4 2010, (vaccines, consumer, respiratory, derma)

  20. Price Competition from Big Pharmaat Jan 2012 • ATORVASTATIN - Ranbaxy in India 5 Rs per tablet - Pfizer in NZ 1 Rs per tablet • CEPHALEXIN - Ranbaxy in India - GSK in India half price

  21. Competition & Risk for Generic Companies

  22. Generics - Rising Risk & Competition

  23. Contagious Price Erosion Across Marketssource: Deutche Bank 22 may 2012

  24. Patent Expiries to 2018source: EvaluatePharma 2012

  25. Global Generic Market Future Growth

  26. Losing Control in the EUsource: Teva June 2012

  27. Stada focus on RussiaSource: Stada

  28. India Compulsory Licence source: ET 13 March 2012

  29. New Measures allow Compulsory licences source: Chemistry World August 2012

  30. Pending USA FDA ANDAs source: Deutsche Bank Jan 2012, 67%

  31. ANDAs from Hisun, China in 2014/15

  32. Indian Company Investment in Discoverysource: Glenmark Annual Report 2012

  33. Biosimilars

  34. Deutsche Bank HK July 2010

  35. Biotech Drugs where India has no DMF Source: JGM Volume 6 p333 sep 2009

  36. Biosimilars from Indian PharmaSource: Deutsche Bank Jan 2012

  37. How much is a Biosimilar worth? Source: Datamonitor

  38. Sandoz Business Model -18 Year Paybacksource: Pharmacloud June 2012

  39. Stada Licence In 2 Biosimilarssource: Stada June 2012

  40. Alliances – the New Faces

  41. Rising Biosimilar Competition • Argentina Government is buying 14 cell lines from a Vancouver Company for local manufacture • In Thailand there are currently 19 EPOs • Celltrion, SK capacity is several 20,000L facilities with enough for the world’s supply • WHO is evaluating 2,000L capacity plants for Palivizumab in LA and Africa

  42. Recent Biosimilar Deals • Cipla & Biomab, China $165m 12 products • Richter & Stada – mABs, 2 products • Celltrion, Korea -Hospira, Egis, Hikma, BB, etc • Biocon & Mylan, USA, mABs • Teva & Lonza, EU – limited range • Biocon Idec & Samsung, Japan • Watson & Amgen, USA • Fuji Film & Kyowa Hakko Kirin • DRL & Merck-Serono, Germany - mABs • Actavis & Bioton, Poland - Insulin • Pfizer & Hisun, China

  43. Will the Tinibs takeover from the mABs?(Tinibs - Tyrosine Kinase Inhibitors -small molecules) • Axitinib, Pfizer, cancer • Cediranib, AZ, cancer • Pazopanib, GSK, cancer • Regorafenib, Bayer, cancer • Semaxanib, Sugen, cancer • Sorafenib, Bayer(Nexavar),cancer • Sunitinib, Pfizer, cancer • Toceranib, Pfizer, cancer • Vandetanib, AZ, cancer • Tofactinib, Pfizer, RA

  44. Biosimilars from China/India Source: New York Times 20 Sep 2011

  45. A New World Order in Pharma is Coming

  46. Thank You brian.tempest@clara.co.uk www.briantempest.com

More Related